The cancer patient and quality of life

Oncologist

Volumn 7, Issue 2, 2002, Pages 120-125

  Bottomley, Andrew ^a  

^a EORTC DATA CENTER   (Belgium)

Author keywords

Cancer; Fatigue; Health related quality of life; rHuEpo; Subjective experience

Indexed keywords

ARTICLE; BELGIUM; CANCER; CANCER PATIENT; CANCER SURVIVAL; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE;

DATA COLLECTION; EUROPE; HUMANS; NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0036227350     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-2-120     Document Type: Article

References (54)

1. Quality of life instruments in oncology
2. The problem of quality of life in medicine
3. Reporting on quality of life in randomised controlled trials: Bibliographic study
4. Quality of life assessment in daily clinical oncology practice: A feasibility study
5. Endpoints in cancer clinical trials: Is there a need for measuring quality of life?
6. What are quality of life measurements measuring?
7. Do quality of life assessments make a difference in the evaluation of cancer treatments?
8. Lessons learned from measuring health-related quality of life in oncology
9. Collecting quality of life data in EORTC clinical trials - What happens in practice?
10. Physicians' and medical students' perspectives on patients' quality of life
11. The use of quality of life data in clinical practice
12. Physicians' perspective on quality of life: An exploratory study of oncologists
13. Oncologists' use of quality of life information results of a survey of Eastern Cooperative Oncology Group physicians
14. Randomized trials with quality of life endpoints: Are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings?
15. Clinician's assessment of quality of life (QOL) in outpatients with advanced cancer: How accurate is our prediction? A Hoosier oncology study
16. Does assessment of quality of life in comparative cancer trials make a difference? A discussion
17. Methodologic assessments of quality of life measures in clinical trials
18. Interpretation of quality of life changes
19. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
20. Distinguishing between quality of life and health status in quality of life research: A meta-analysis
21. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology
22. Do we know what global ratings of health-related quality of life measure?
23. Methodological issues in the assessment of health-related quality of life in palliative care trials
24. Determining a minimal important change in a disease-specific Quality of Life Questionnaire
25. Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: Does quality of life matter?
26. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer
27. Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: From advanced disease to adjuvant therapy
28. Symptom reporting in cancer patients II: Relations to social desirability, negative affect, and self-reported health behaviors
29. Interpreting the significance of changes in health-related quality-of-life scores
30. Quality of life assessment. An independent prognostic variable for survival in lung cancer
31. Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease. The importance of patients' subjective experience of disease and psychosocial well-being
32. Improving the quality of life during chemotherapy for advanced breast cancer: A comparison of intermittent and continuous treatment strategies
33. Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer
34. Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: Quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist
35. Doxorubicin in advanced breast cancer: Influence of schedule on response, survival and quality of life
36. Evaluation of quality of life in patients receiving treatment for advanced breast cancer
37. Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast
38. Oral clodronate in breast cancer patients with bone metastases: A randomized study
39. Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group
40. Guidelines for reporting results of quality of life assessments in clinical trials
41. Quality-of-life assessment: Patient compliance with questionnaire completion
42. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
43. Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer
44. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial
45. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: A phase I-II study
46. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
47. Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer
48. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - A randomized trial with quality of life as the primary outcome
49. Quality-of-life assessment in cancer treatment protocols: Research issues in protocol development
50. Measuring the quality of life of cancer patients: Psychometric properties of instruments
51. Quality of life in cancer patients - An hypothesis
52. Assessment of treatment of cancer
53. Assessment of quality of life in clinical trials
54. Study protocol for the World Health Organization project to develop a quality of life assessment instrument (WHOQOL)